Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
Alnylam Pharmaceuticals Is Maintained at Buy by UBS
Express News | Alnylam Pharmaceuticals Inc : UBS Raises Target Price to $288 From $253
One graphic to understand | the June bull and bear stocklist of U.S. stocks is released! Optional consumer and technology sectors are performing strongly, Arm rose more than 38%, and Adobe rose nearly 23%.
The three major US stock indexes rose collectively this month, putting a perfect end to the first half of the year. Large-cap tech stocks continued their rally, driving the Nasdaq up by 6.71% this month, the best performer. The S&P 500 rose 3.89% this month and the Dow Jones rose 1.23%.
UBS Initiates Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $288
UBS analyst Eliana Merle initiates coverage on $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and sets the target price at $288.According to TipRanks data, the analyst has a success rate of 40.
Alnylam Pharmaceuticals(ALNY.US) Director Sells US$2.04 Million in Common Stock
$Alnylam Pharmaceuticals(ALNY.US)$ Director SCHULMAN AMY W sold 8,500 shares of common stock on Jun 25, 2024 at an average price of $240 for a total value of $2.04 million.Source: Announcement What is
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals Is Maintained at Outperform by RBC Capital
Alnylam Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $295
Stifel analyst Paul Matteis maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and adjusts the target price from $247 to $295.According to TipRanks data, the analyst has a success rate of
Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $265
RBC Capital analyst Luca Issi maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and adjusts the target price from $250 to $265.According to TipRanks data, the analyst has a success rate
US Stock | Amazon joins the "Trillion-Dollar Market Cap Club"; Rivian soars more than 23% overnight.
Microsoft hit a new all-time high overnight, with a cumulative increase of over 20% since the beginning of the year; Fedex rose more than 15% overnight, exceeding expectations for the 2025 fiscal year guidance and receiving a bullish rating from Goldman Sachs.
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $250
Morgan Stanley analyst Michael Ulz maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a hold rating, and maintains the target price at $250.According to TipRanks data, the analyst has a success rate of
Express News | Alnylam Pharmaceuticals Inc : RBC Raises Target Price to $265 From $250
Alnylam Pharmaceuticals(ALNY.US) Director Sells US$7.16 Million in Common Stock
$Alnylam Pharmaceuticals(ALNY.US)$ Director PYOTT DAVID E I sold 32,450 shares of common stock on Jun 24, 2024 at an average price of $221 for a total value of $7.16 million.Source: Announcement What
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing
10 Health Care Stocks Whale Activity In Today's Session
Alnylam Pharmaceuticals on Track for Record High Close -- Data Talk
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $234 to $291
On Jun 26, major Wall Street analysts update their ratings for $Alnylam Pharmaceuticals(ALNY.US)$, with price targets ranging from $234 to $291.Morgan Stanley analyst Michael Ulz maintains with a hold